A Study of 18F-AlF-NOTA-octreotide PET/CT for Imaging Neuroendocrine Neoplasms

• Status: Unknown status
• Trial end date: 2020-12-30
• Target enrollment: 0
• Participant gender: All

Summary

The aim of this study is to investigate the clinical value of [18F]aluminum fluoride-1,4,7-triazacyclononane-1,4,7-triacetic acid-octreotide（18F-AlF-NOTA-octreotide ） positron emission tomography / computed tomography (PET/CT) in patients with neuroendocrine neoplasms (NENs).

• Phase: Phase 1/Phase 2
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Xiangya Hospital of Central South University
• Treatments: Octreotide

Criteria

Inclusion Criteria:

1. Histologically and/or clinically confirmed and/or suspicious of NEN.

2. Signed informed consent.

Exclusion Criteria:

1. Claustrophobia (unable to accept PET/CT scanning)

2. Pregnant or breast-feeding